Clinical trials: acne
Acne Vulgaris
Acne Vulgaris Related Microbiology and Serology
This will be an investigation to determine the quality of the serological immune responses against Propionibacterium acnes (P. acnes) in acne patients compared to healthy individuals.
- Trial name
- NCT04056598
- Testing
- Study of humoral immunity
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sanofi
Acne, Healthy
Assessment of Biological, Biometrological Parameters and Consumer Needs in Adult Subjects with Acne
Acne vulgaris (acne) is a chronic inflammatory pathology of the pilosebaceous unit. Its prevalence is about 85% of teenagers and is constantly increasing in adults, especially women.
- Trial name
- NCT06841393
- Testing
- Biometrological measurements, Biological sampling, Clinical assessments
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermo Cosmetique
Acne Vulgaris
Differin® Gel x12 Wks vs Tazorac® Cream x12 Wks vs Differin® x6 Wks Switched to Tazorac® x6 Wks for Treatment of Acne
To determine the efficacy and safety of 12 weeks of treatment with Differin Gel, 0.1% compared to 12 weeks of treatment with Tazorac Cream, 0.1% and compared to 6 weeks treatment with Differin Gel, 0.1% followed by 6 weeks of…
- Trial name
- NCT00469755
- Testing
- Adapalene Gel, 0.1%, Tazarotene Cream, 0.1%, Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%
- Where
- 12 sites in United States
- Volunteers
- 302 people
- Sponsor
- Galderma R&D
Wrinkles, Acne Scars
Epidermal Delivery of Ani-Aging Ingredients
To assess the safety and efficacy of an ablative fractional, 2940-nm laser combined with the US Impact and cosmetic -formulations for improving the appearance of wrinkles, acne scars and pigmented skin.
- Conditions
- Wrinkles, Acne Scars, Pigmentation
- Trial name
- NCT01847066
- Testing
- Erbium 2940 plus cosmetics plus Impact, Erbium 2940 plus cosmetics
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Alma Lasers Inc.
Moderate to Severe Acne Vulgaris
Study on Using Radiofrequency to Treat Moderate to Severe Acne
Evaluation of the safety and efficacy of fractional radiofrequency for the treatment of moderate to severe acne vulgaris.
- Trial name
- NCT06315166
- Testing
- triLift/Legend Pro+ Fractional RF System
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pollogen
Acne Vulgaris
Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris
To compare the safety and efficacy of the test (Trifarotene 0.005% cream), placebo (vehicle cream) and reference AKLIEF® (Trifarotene 0.005% cream) treatments to demonstrate clinical equivalence in subjects with acne vulgaris.
- Trial name
- NCT05550337
- Testing
- Trifarotene 0.005 % Topical Cream, AKLIEF®
- Where
- 14 sites in United States
- Volunteers
- 807 people, healthy volunteers welcome
- Sponsor
- Teva Pharmaceuticals USA
Acne Vulgaris
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris
To evaluate the therapeutic equivalence and safety of Adapalene Gel 0.3% (Aleor Dermaceuticals Limited, India) and Differin® (Adapalene) Gel 0.3% (Galderma Laboratories, LP USA) in the treatment of acne vulgaris.
- Trial name
- NCT03650361
- Testing
- Adapalene Gel 0.3%, Differin 0.3% Topical Gel
- Where
- 10 sites in United States, Belize
- Volunteers
- 755 people
- Sponsor
- Aleor Dermaceuticals Limited
Acne Vulgaris
Treatment of Moderate to Severe Facial Acne Vulgaris
Randomized, multi-center, double-blind, placebo-controlled 12-week study to assess the safety and efficacy of 3 doses of an oral formulation of Doxycycline oral tablets using the Investigator's Global Assessment (IGA) score and…
- Trial name
- NCT00612573
- Testing
- Doxycycline 0.6 mg/kg/day, Doxycycline 1.2 mg/kg/day, Doxycycline 2.4 mg/kg/day
- Where
- 23 sites in United States
- Volunteers
- 257 people
- Sponsor
- Warner Chilcott
Acne Vulgaris
A Study To Evaluate The Safety And Therapeutic Equivalence of Tazarotene Foam 0.1% in Subjects With Acne Vulgaris
The purpose of this study is to compare the safety and therapeutic equivalence of a generic tazarotene foam 0.1% and the reference listed Fabior™ (tazarotene foam, 0.1%) in the treatment of acne vulgaris.
- Trial name
- NCT02267746
- Testing
- Tazarotene (Fabior™), Tazarotene (Actavis), Vehicle foam
- Where
- 15 sites in United States, Belize
- Volunteers
- 893 people
- Sponsor
- Actavis Inc.
Acne Vulgaris
Skin Acceptance and Efficacy Assessment of a Topical Product in Acne Treatment When Compared to a Placebo.
In this study the topical use of cream with live probiotic bacteria was evaluated for its efficacy in reducing acne symptoms and its effect on the skin microbiota on patients with acne vulgaris.
- Trial name
- NCT04216160
- Testing
- ACN cream (YUN)
- Where
- Brazil
- Volunteers
- 80 people
- Sponsor
- YUN NV
Acne Vulgaris
A Safety, Tolerability, Efficacy and Exposure Study of XEN801 Topical Gel
Phase 1/2 study enrolling up to 60 healthy volunteers in Phase 1 followed by approximately 150 subjects with acne vulgaris in Phase 2.
- Trial name
- NCT02656043
- Testing
- XPF-005
- Where
- 20 sites in Canada
- Volunteers
- 213 people, healthy volunteers welcome
- Sponsor
- Xenon Pharmaceuticals Inc.
Acne Scars - Mixed Atrophic and Hypertrophic, Ice Pick Scars
Evaluation of Efficacy and Safety of HCC_45 for the Correction of Acne Scars of the Face
Acne scars represent a frequent complication of moderate/severe acne and may negatively impact on psychosocial and physical well-being of acne patients.
- Conditions
- Acne Scars - Mixed Atrophic and Hypertrophic, Ice Pick Scars, Rolling Scars, Boxcar Scars
- Trial name
- NCT05691049
- Testing
- HCC_45
- Where
- Italy
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- IBSA Farmaceutici Italia Srl
Acne Vulgaris
Efficacy and Safety Study With Visonac Photodynamic Therapy (PDT)
The purpose of this trial is to study the efficacy and safety of Visonac PDT in patients from 9 to 35 years old with Aktilite® CL512.
- Trial name
- NCT00933543
- Testing
- Visonac PDT (MAL PDT), PDT
- Where
- 11 sites in United States, Canada
- Volunteers
- 107 people
- Sponsor
- Photocure
Acne Vulgaris
Safety Study of Plasma Treatment System to Treat Back Acne
The purpose of this study is to evaluate the safety of treating human skin with atmospheric plasma and get an initial evaluation of the efficacy of this treatment for acne.
- Trial name
- NCT01662349
- Testing
- MOE Antimicrobial Plasma Treatment System
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Moe Medical Devices
Atrophic Acne Scar
A Study to Evaluate the Efficacy of ELAPR002f in Females and Males With Atrophic Acne Scars
The study is designed to evaluate the efficacy of two formulations of a cross-linked tropoelastin matrix given the product codes ELAPR002f (collectively referred to as ELAPR or ELAPR002) for the treatment of rolling atrophic acne…
- Trial name
- NCT03056235
- Testing
- ELAPR002f, Saline
- Where
- United Kingdom
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Elastagen Pty Ltd
Acne Vulgaris
Photodynamic Therapy (PDT) With Methyl Aminolevulinate (MAL) Cream in Moderate to Severe Acne
This multicenter study will be divided into 2 phases. The first phase will be an open label, dose-escalation phase, while the second will be a blinded, randomized, vehicle-controlled, parallel-group, dose-response phase.
- Trial name
- NCT00594425
- Testing
- Methyl aminolevulinate (MAL) PDT
- Where
- 14 sites in United States
- Volunteers
- 150 people
- Sponsor
- Photocure
Acne Vulgaris
Effectiveness and Tolerance of Effaclar Serum in Women With Mandibular Acne
The role of "dermocosmetics" in acne management is increasingly important, as many patients and even physicians now resort to them as first-line management in mild-to-moderate acne.
- Trial name
- NCT05457621
- Testing
- Effaclar serum
- Where
- France
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Acne Vulgaris
A Bioequivalence Study With Clinical Endpoints Comparing Adapalene and Benzoyl Peroxide Topical Gel 0.1%/2.5% (Actavis Mid-Atlantic LLC) To Epiduo™ (Adapalene and Benzoyl Peroxide) Gel 0.1%/2.5% (Galderma Laboratories, L.P.) in the Treatment of Mild to Severe Acne Vulgaris
EPIDUO™ (adapalene and benzoyl peroxide) Gel 0.1%/2.5%, marketed by GALDERMA LABORATORIES, L.P., is a safe and effective topical therapy used for the treatment of acne vulgaris.
- Trial name
- NCT01501799
- Testing
- adapalene 0.1% and benzoyl peroxide 2.5% topical gel, EPIDUO
- Where
- 25 sites in United States, Belize and 1 more
- Volunteers
- 885 people
- Sponsor
- Actavis Mid-Atlantic LLC
Acne Vulgaris
To Study Generic Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Glenmark Generics, Ltd) in the Treatment of Acne Vulgaris.
This is a randomized, double-blind, multiple-site, placebo-controlled, parallel-group study, designed to compare the efficacy and safety of generic Clindamycin 1%/ Benzoyl peroxide 5% topical gel (Glenmark Generics, Ltd), and the…
- Trial name
- NCT02465632
- Testing
- Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel, BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%
- Where
- 15 sites in United States, Belize
- Volunteers
- 1,100 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Acne Vulgaris
W0261-101: A Phase 1, Single Center, Randomized, Open-Label Study to Evaluate the Bioavailability of Clindamycin From Clindamycin 1%-Benzoyl Peroxide 3% Gel, Topical Gel (Clindamycin 1%- Benzoyl Peroxide 5%), and Once Daily Gel (Clindamycin 1%-Benzoyl Peroxide 5%) in Subjects With Acne
This study was conducted to determine if the bioavailability of clindamycin and its metabolite clindamycin sulfoxide are altered by the concentration of BPO or the absence of methylparaben.
- Trial name
- NCT01132443
- Testing
- Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,
- Volunteers
- 72 people
- Sponsor
- Stiefel, a GSK Company